# Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

> **NCT00877006** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 447 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** bendamustine
- **DRUG:** rituximab
- **DRUG:** vincristine
- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT00877006
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-30
- **Primary completion:** 2012-03-31
- **Final completion:** 2012-03-31
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877006, "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00877006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*